NRX Pharmaceuticals, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
NRX Pharmaceuticals, Inc. (NRXP) reported Cash and Cash Equivalents, Period Increase (Decrease) of $25.75 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-31.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2022-08-12
- NRX Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2021-12-31 was -$11.28M, a 2073.02% decline year-over-year.
- NRX Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2021-09-30 was $25.50M, a 8638.75% increase year-over-year.
- NRX Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2021-06-30 was $11.53M, a 30400.72% increase year-over-year.
- NRX Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2021-03-31 was -$234.00, a 100.29% decline year-over-year.
- NRX Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2021 was $25.75M, a 2521.79% increase from fiscal 2020.
- NRX Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2020 was $982.00K.
- NRX Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2019 was -$11.07K.
- NRX Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2018 was -$438.30K.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | -$11.28M derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-03-31 | $14.22M derived: sum of 2 quarters · filed 2022-08-12 | $25.75M derived: sum of 3 quarters · filed 2022-08-12 | $25.75M 10-K · filed 2022-03-31 | |||
| 2021-09-30 | $25.50M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2022-08-12 | $37.03M derived: sum of 2 quarters · filed 2022-08-12 | $37.03M 10-Q/A · filed 2022-08-12 | $37.60M derived: sum of 4 quarters · filed 2022-08-12 | |||
| 2021-06-30 | $11.53M derived: 10-Q/A 6 month − 10-Q 3 month · filed 2022-08-12 | $11.53M 10-Q/A · filed 2022-08-12 | $12.10M derived: sum of 3 quarters · filed 2022-08-12 | $12.39M derived: sum of 4 quarters · filed 2022-08-12 | |||
| 2021-03-31 | -$234.00 10-Q · filed 2021-05-21 | $571.43K derived: sum of 2 quarters · filed 2022-03-31 | $863.20K derived: sum of 3 quarters · filed 2022-08-12 | $901.00K derived: sum of 4 quarters · filed 2022-08-12 | |||
| 2020-12-31 | $571.66K derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-03-31 | $863.44K derived: sum of 2 quarters · filed 2022-08-12 | $901.23K derived: sum of 3 quarters · filed 2022-08-12 | $982.00K 10-K · filed 2022-03-31 | $460.00 10-K · filed 2021-04-01 | ||
| 2020-09-30 | $291.77K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2022-08-12 | $329.57K derived: sum of 2 quarters · filed 2022-08-12 | $410.34K 10-Q/A · filed 2022-08-12 | $40.01K 10-Q · filed 2020-11-16 | $216.06K derived: sum of 4 quarters · filed 2022-08-12 | ||
| 2020-06-30 | $37.80K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2022-08-12 | $118.56K 10-Q/A · filed 2022-08-12 | $1.00 10-Q · filed 2020-08-14 | -$75.71K derived: sum of 3 quarters · filed 2022-08-12 | $117.18K derived: sum of 4 quarters · filed 2022-08-12 | ||
| 2020-03-31 | $80.77K 10-Q · filed 2021-05-21 | -$113.51K derived: sum of 2 quarters · filed 2021-05-21 | $79.38K derived: sum of 3 quarters · filed 2021-05-21 | $78.96K derived: sum of 4 quarters · filed 2021-05-21 | |||
| 2019-12-31 | -$194.27K derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-05-14 | -$1.39K derived: sum of 2 quarters · filed 2021-05-14 | -$1.81K derived: sum of 3 quarters · filed 2021-05-14 | -$11.07K 10-K/A · filed 2021-05-14 | |||
| 2019-09-30 | $192.89K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $192.46K derived: sum of 2 quarters · filed 2020-11-16 | $183.20K 10-Q · filed 2020-11-16 | $117.19K derived: sum of 4 quarters · filed 2020-11-16 | |||
| 2019-06-30 | -$424.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | -$9.69K 10-Q · filed 2020-08-14 | -$75.69K derived: sum of 3 quarters · filed 2020-08-14 | -$138.22K derived: sum of 4 quarters · filed 2020-08-14 | |||
| 2019-03-31 | -$9.26K 10-Q · filed 2020-05-15 | -$75.27K derived: sum of 2 quarters · filed 2020-05-15 | -$137.79K derived: sum of 3 quarters · filed 2020-05-15 | -$265.37K derived: sum of 4 quarters · filed 2020-05-15 | |||
| 2018-12-31 | -$66.01K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | -$128.53K derived: sum of 2 quarters · filed 2020-03-30 | -$256.11K derived: sum of 3 quarters · filed 2020-03-30 | -$438.30K 10-K · filed 2020-03-30 | |||
| 2018-09-30 | -$62.53K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$190.10K derived: sum of 2 quarters · filed 2019-11-14 | -$372.29K 10-Q · filed 2019-11-14 | $82.47K 10-Q · filed 2018-11-08 | |||
| 2018-06-30 | -$127.58K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$309.76K 10-Q · filed 2019-08-14 | $139.61K derived: sum of 3 quarters · filed 2019-08-14 | ||||
| 2018-03-31 | -$182.18K 10-Q · filed 2019-05-15 | $267.19K derived: sum of 2 quarters · filed 2019-05-15 | |||||
| 2017-12-31 | $449.37K 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |